Epitopea, a clinical-stage, biotech company developing off-the-shelf, durable RNA-based cancer vaccines, announced today that the first patient has been successfully dosed in OVACT, its first-in-human ...

This biological insight has established opportunistic salpingectomy as a promising strategy for primary prevention. The procedure involves performing opportunistic salpingectomy during otherwise ...

A single-cell transcriptomics study reveals that conserved fallopian tube epithelial programs drive chemoresistance and ...

Cambridge biotech Epitopea doses first patient in its UK Phase 1 clinical trial of CryptiVax-1001, a novel mRNA cancer ...

A new research paper was published in Volume 12 of Oncoscience on October 14, 2025, titled "Bridging clinical insight and laboratory model in high-grade serous ovarian carcinoma (HGSOC) using DNA ...

Opportunistic salpingectomy (OS) is feasible but not performed in almost a quarter of patients later diagnosed with high-grade serous carcinoma (HGSC), and about 40% of patients with a first-degree ...

Several factors make ovarian cancer particularly challenging to treat. This is largely because the cancer often spreads at a microscopic level within the abdomen early on, resulting in diagnosis at an ...

Additional research on novel targeted therapies may be necessary to address the unmet needs in this high-grade serous ovarian cancer population. Combining alpelisib (Piqray) with olaparib (Lynparza) ...

Scientists at The University of Texas at El Paso have found a promising new target in the fight against high-grade serous carcinoma, an aggressive form of ovarian cancer. Less than 50 percent of women ...

Nearly 40% of low-grade serous ovarian cancers have RAS alterations, which are predominately KRAS mutations. Despite low-grade serous ovarian cancer’s characterization as an epithelial ovarian cancer ...